Head Diagnostics signs global licence with Philips to advance early brain health detection

Irish medtech firm Head Diagnostics has secured an exclusive global licence from Philips for a digital cognitive assessment platform, now rebranded as HDx Cognition. The platform empowers clinicians to detect cognitive decline—such as dementia and Alzheimer’s—early, unlocking timely intervention as new neuroprotective therapies gain ground.

Operating on iPad and deployable across GP clinics, hospitals, pharmacies, and even at home, HDx Cognition brings clinically validated brain health screening into everyday healthcare. It also integrates mental health assessments like GAD-7 and PHQ-9, creating a more complete picture of cognitive and emotional wellbeing.

With plans to enhance the platform through AI, remote monitoring, and multimodal inputs, Head Diagnostics is positioning itself at the forefront of the global digital neurodiagnostic market—estimated to be worth billions.

Read the full story on how this deal is reshaping the future of brain health diagnostics.